Metformin added to insulin therapy for type 1 diabetes mellitus in adolescents

Cochrane Database of Systematic Reviews

Volumn , Issue 1, 2009, Pages

  Abdelghaffar, Shereen ^a   Attia, Abdelhamid M ^b  

^a CAIRO UNIVERSITY   (Egypt)

^b CAIRO UNIVERSITY   (Egypt)

Author keywords

Adolescent; Diabetes mellitus, type 1 *drug therapy ; Drug therapy, combination; Humans; Hypoglycemic agents *administration dosage ; Insulin *administration dosage ; Metformin *administration dosage ; Randomized controlled trials as topic

Indexed keywords

HEMOGLOBIN A1C; INSULIN; LIPID; METFORMIN; PLACEBO;

BODY COMPOSITION; CLINICAL TRIAL; COCHRANE LIBRARY; DIARRHEA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EMBASE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INSULIN TREATMENT; KETOACIDOSIS; LACTIC ACIDOSIS; LIPID BLOOD LEVEL; MEDLINE; META ANALYSIS; METABOLIC REGULATION; MORBIDITY; MORTALITY; NAUSEA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING;

EID: 70249141208     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006691.pub2     Document Type: Review

References (42)

1. *Hamilton J, Cummings E, Zdravkovic V, Finegood D, Daneman D. Metformin as an adjunct therapy in adolescents with type 1 diabetes and insulin resistance. Diabetes Care 2003;26:138-143
2. Sarnblad S, Kroon M, Aman J. Metformin as additional therapy in adolescents with poorly controlled type 1 diabetes: randomized placebo-controlled trial with aspects on insulin sensitivity. European Journal of Endocrinology 2003;149:323-329
3. Schatz H, Winkler G, Jonatha EM, Pfeiffer EF. Studies on juvenile -type diabetes in children. Assessment of control under treatment with constant and variable doses of insulin with or without addition of biguanides. Diabete & Metabolisme 1975;1:211-220.
4. Walravens PA, Chase PH, Klingensmith GJ, Ellison M, Cornell C, Monahan K. [Low dose metformin in adolescents with type 1 diabetes: a double-blind, controlled study. (Abstract).]. Diabetes. 2000:49 A128.
5. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1999;22 Suppl 1:S5-19.
6. Aldasouki SA, Duick DS. Safety issues on Metformin use. Diabetes Care 2003;26:3356-3357
7. Bending JJ, Collins AC, Keen H. Metformin increases response to insulin in insulin-dependent diabetes. Diabet Med. 1987; Vol.46: 555A.
8. Bergman RN. Lilly Lecture: Toward physiological understanding of glucose tolerance: minimal-model approach (Review).. Diabetes 1989;38:1512-1527.
9. Caprio S, Cline G, Boulware S, Permante C, Shulman GI, Sherwin RS, et al.Effects of puberty and diabetes on metabolism of insulin-sensitive fuels. American Journal of Physiology 1994;266:E885-E91.
10. Cohen J. A coefficient of agreement for nominal scales. Educational and Psychological Measurement 1960;20:37-46.
11. Coscelli C, Palmari V, Saccardi F, Orsola A, Bonnora E. Effect of Metformin addition to insulin in type 1 diabetes mellitus.. Front Diabetes 1984;4:253-257.
12. Daniel JR, Hagmeyer KO. Metformin and insulin: is there a role for combination therapy?. Annals of Pharmacotherapy 1997;31:474-480
13. DCCT Research Group. Effect of intensive diabetes treatment on the development and progression of long-term complications in adolescents with insulin-dependent diabetes mellitus. Diabetes Control and Complications Trial. Journal of pediatrics 1994;125:177-188
14. Desmangles J, Buchlis JG, Shine B, Quattrin T. Is Metformin a useful adjunct to insulin therapy in adolescents with type 1 diabetes in poor control?. Endocrine Society Meeting, Abstract 1833. 2000.
15. Faichney JD, Tate PW. Metformin in type 1 diabetes: is this a good or bad idea?. Diabetes Care 2003;26(5):1655.
16. Gin H, Slama G, Weissbrodt P, Poynard T, Vexiau P, Klein J, Tchobrousky G. Metformin reduces post-prandial insulin needs in type 1 (insulin-dependent) diabetic patients: assessment by the artificial pancreas. Diabetologia 1982;23:34-36
17. Golay A, Guillet-Dauphine N, Fendel A, Juge C, Assal JP. The insulin- sparing effect of metformin in insulin-treated diabetic patients. Diabetes/Metabolism Reviews 1995;11:S63-S67.
18. Halldin MU, Tylleskar K, Hagenas L, Tuvemo T, Gustafsson J. Is growth hormone hypersecretion in diabetic adolescent girls also a daytime problem? growth hormone hypersecretion in diabetic adolescent girls also a daytime problem?. Clinical Endocrinology 1998; 48:785-794
19. Higgins JPT, Thompson SG. Quantifying heterogeneity in a metaanalysis. Statistics in medicine 2002;21:1539-1558
20. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analysis. BMJ 2003;327:557-560
21. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.0 [updated February 2008]. The Cochrane Collaboration. Available from www.cochrane-handbook.org, 2008.
22. Howlett HCS, Bailey CJ. A risk-benefit assessment of metformin in type 2 diabetes mellitus. Drug safety 1999;20:489-503.
23. Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000;49:2063-2069
24. Jadad A, Moore A, Carrol D, et al. Assessing the quality of randomized trials: Is blinding necessary?. Controlled Clinical Trials 1996;17:1-12.
25. Janssen M, Rillaerts E, De Leeuw I. Effects of metformin on haemorheology, lipid parameters and insulin resistance in insulin-dependent diabetic patients (IDDM). Biomedicine & Pharmacotherapy 1991;45:363-367
26. Jones KL, Arslanian S, Peterokova VA, Park J-S, Tomlinsson MJ. Effect of metformin in pediatric patients with type 2 diabetes. Diabetes Care 2002;25:89-94.
27. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. BMJ 2006;333:597-600.
28. Mehnert H. Metformin, the rebirth of a biguanide: mechanism of action and place in the prevention and treatment of insulin resistance. Experimental and Clinical Endocrinology and Diabetes 2001; 109:S259-S264.
29. Meyer L, Bohme P, Delbachian I, Lehert P, Cugnardey N, Drouin P, et al. The benefits of metformin therapy during continuous subcutaneous insulin infusion treatment of type 1 diabetic patients. Diabetes Care 2002;25:2153-2158
30. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin (Letter). New England Journal of Medicine 1998;338:265-266
31. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports ofmeta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999;354(9193):1896- 1900
32. Mortensen HB, Robertson KJ, Aanstoot HJ, Danne T, Holl RW, Hougaard P, et al. Insulin management and metabolic control of type 1 diabetes mellitus in childhood and adolescence in 18 countries. Hvidore Study Group on Childhood Diabetes. Diabetic Medicine 1998;15:752-759
33. Pagano G, Tagliaferro V, Carta Q, Caselle M, Bozzo C, Vitelli F, et al.Metformin reduces insulin requirement in type 1 (insulin-dependent) diabetes. Diabetologia 1983;24:351-354
34. Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D. Metformin monotherapy for type 2 diabetes. Cochrane Database of Systematic Reviews 2005, Issue 3. [DOI: 10.1002/14651858.CD002966.pub3]
35. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and non fatal lactic acidosis with Metformin use in type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2005, Issue 1. [DOI: 10.1002/14651858.CD002967. pub2]
36. Schultz KF, Chalmers I, Hayes RJ, Altman DJ. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995;273:408-412
37. Sterne JAC, Egger M, Davey Smith G. Investigating and dealing with publication and other biases. In: Egger M, Davey Smith G, Altman DG editor(s). Systematic Reviews in Health Care; Meta-analysis in Context. London: BMJ Publishing Group, 2001:189-208.
38. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control withmetformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854-865
39. WHO Expert Committee on Diabetes Mellitus. Second report. Technical Report Series 646. Geneva. WHO, 1980.
40. WHO Expert Committee on Diabetes Mellitus. World Health Organization, 1985. Technical Report Series 727.
41. Alberti KM, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its compliactions. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine 1998;15:539-553
42. Yki-Jarvinen H, Makimattila S -Jarvinen H, Makimattila S. Insulin resistance due to hyperglycaemia: an adaptation protecting insulinsensitive tissues. Diabetologia 1997;40:S141-S144.